De novo lupus nephritis in a renal transplanted child: a case report.

Transplant Proc

Department of Pathology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.

Published: December 2014

De novo lupus nephritis (LN) is a rare complication in renal transplantation recipients. We present the clinical manifestations of de novo LN in a 12-year-old boy who received a cadaveric renal transplant. The cause of end-stage renal disease was prune belly syndrome with renal dysplasia. His immunosuppressive drugs included tacrolimus, mycophenolate sodium, and prednisolone. After 3 years of treatment, he developed nephrotic syndrome (NS) without other symptoms of systemic lupus erythematosus (SLE). The renal pathology of the transplanted kidney showed suspicious acute cellular rejection and LN World Health Organization class IV-G (A/C). Antinuclear antibody was positive, but anti-dsDNA and anti-Smith were negative. The serum complements were initially normal. Pulse methylprednisolone was given and the dosages of all immunosuppressive drugs increased; notwithstanding, his edema and hypoalbuminemia worsened. Repeated biopsy of the transplanted kidney was done. A full-house pattern was documented under immunofluorescent examination which confirmed LN WHO class IV-G (A/C) without evidence of rejection. He then developed macrophage-associated hemophagocytic syndrome and cytomegalovirus pneumonia. He ultimately developed pulmonary hemorrhage and died owing to severe pneumonia. De novo LN should be considered in renal transplant recipients with new onset of NS despite there not being any other clinical manifestations of SLE.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.transproceed.2013.12.023DOI Listing

Publication Analysis

Top Keywords

novo lupus
8
lupus nephritis
8
clinical manifestations
8
renal transplant
8
immunosuppressive drugs
8
transplanted kidney
8
class iv-g
8
iv-g a/c
8
renal
7
novo
4

Similar Publications

Design of minibinder proteins specific to TNFR1.

Int J Biol Macromol

December 2024

State Key Laboratory of Biocatalysis and Enzyme Engineering, School of Life Sciences, Hubei University, Wuhan, Hubei 430062, China; National & Local Joint Engineering Research Center of High-throughput Drug Screening Technology, School of Life Sciences, Hubei University, Wuhan, Hubei 430062, China; Hubei Jiangxia Laboratory, Wuhan, Hubei 430200, China. Electronic address:

TNFα inhibitors have been successfully developed and used in the clinical treatment of autoimmune disorders. However, the use of TNFα blockade may be accompanied by side effects. The cases of bacterial and viral infections, lymphoproliferative disorders, and anti-TNFα-induced lupus, have been reported among the rheumatoid arthritis or Crohn's disease patients treated with TNFα blockers.

View Article and Find Full Text PDF

Background: Systemic Lupus Erythematosus (SLE) (C1) is a disease with multi-organ involvement that can have a variety of cutaneous manifestations in 76% of cases during the disease. Less than 1% of these patients are diagnosed with confirmed bullous systemic lupus erythematosus (C1). Given the wide differential diagnosis of a bullous lesion, it is imperative to reach a conclusive diagnosis as it can have a direct impact on the course of management of the disease.

View Article and Find Full Text PDF

Intracranial hypertension as the first manifestation of systemic lupus erythematosus: A case report.

Heliyon

October 2024

Universidad Icesi, CIRAT: Centro de Investigación en Reumatología, Autoinmunidad y Medicina Traslacional, Calle 18 No. 122 -135, Cali, Colombia.

Introduction: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects multiple systems and organs, including the central and peripheral nervous systems. Papilledema and idiopathic intracranial hypertension, in the absence of space-occupying lesions or other detectable causes, is a rare manifestation. We report the case of a young woman with chronic headache, papilledema, and intracranial hypertension on examination, in whom a de novo diagnosis of systemic lupus erythematosus and class V lupus nephritis was made.

View Article and Find Full Text PDF
Article Synopsis
  • Autoimmune diseases like systemic lupus erythematosus (SLE) and psoriasis have been linked to a higher risk of atherosclerotic cardiovascular disease (ASCVD), but the impact of cutaneous lupus erythematosus (CLE) on ASCVD risk is uncertain.
  • A study aimed to compare the incidence and prevalence of ASCVD among patients with CLE, SLE, and psoriasis against a control group without these diseases, utilizing data from a large health database.
  • The results showed that individuals with CLE and SLE had significantly higher odds of developing ASCVD compared to the control group, but psoriasis did not show the same increased risk.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!